Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Lanreotide (Somatuline Depot) peptide icon, one bubble per amino acidLanreotide (Somatuline Depot)8 residuesXCYWKVCTEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Lanreotide (Somatuline Depot)

Beginner tier: 90 mg, every 4 weeks · FDA label

MetabolicFDA Approved
~23-30 days half-life·Injection

Also known as: Somatuline Depot, Somatuline Autogel, BIM-23014

The CLARINET trial cut tumor progression risk by 53% in patients with gastroenteropancreatic neuroendocrine tumors. Lanreotide (brand name Somatuline Depot) is a synthetic somatostatin analog, an eight-amino-acid cyclic peptide that mimics the body's own growth hormone brake. It earned FDA approval for acromegaly in 2007 and for GEP-NETs in 2014. One deep subcutaneous injection every 28 days from a pre-filled syringe replaces what used to require daily shots. The trade-off is real: diarrhea hits 35 to 65% of patients early on, and gallstones develop in roughly one in four long-term users. Endocrinologists and oncologists prescribe it when pituitary tumors overproduce growth hormone or when neuroendocrine tumors need slowing down.

What Is Lanreotide (Somatuline Depot)?

A 53% reduction in tumor progression risk. That single number from the CLARINET trial (204 patients with GEP-NETs)[1] turned lanreotide into a cornerstone of neuroendocrine tumor management.

Lanreotide (Somatuline Depot, CAS 108736-35-2) is a cyclic octapeptide analog of somatostatin. It binds somatostatin receptor subtypes SST2 and SST5 with high and moderate affinity, respectively. That receptor activation does two things: it shuts down excess growth hormone and IGF-1 secretion from pituitary somatotrophs, and it triggers antiproliferative signaling in neuroendocrine tumor cells. The depot formulation uses a supersaturated poloxamer gel that forms a slow-release deposit at the injection site, maintaining therapeutic drug levels for a full 28-day cycle.

In practice, most patients fall into two camps. Acromegaly patients receive 90 mg every 28 days as a starting dose, titrated between 60 and 120 mg based on GH and IGF-1 levels. The PRIMARYS trial [2] tracked 90 treatment-naive acromegaly patients and found 63% achieved at least 20% pituitary tumor shrinkage by week 48. GEP-NET patients receive a fixed 120 mg every 28 days. CLARINET showed median progression-free survival of 32.8 months versus 18.0 months on placebo.

The 2025 STARTER-NET trial added a new wrinkle: combining lanreotide with everolimus pushed median PFS from 13.6 to 29.7 months in higher-risk GEP-NETs (HR 0.44, p=0.00016). A generic version from Cipla received FDA approval in May 2024, bringing costs down from about $4,200 to roughly $2,435 per 120 mg injection. Side effects are front-loaded; diarrhea and abdominal pain hit hardest in the first few months, and long-term gallstone monitoring is non-negotiable.

How Lanreotide (Somatuline Depot) Works

Somatostatin is the body's built-in hormone brake. It circulates briefly, with a half-life under three minutes, then gets cleared. Lanreotide copies that molecule's receptor-binding structure but locks it into a cyclic octapeptide that persists for weeks instead of seconds.

The primary target is somatostatin receptor subtype 2 (SST2). When lanreotide binds SST2 on pituitary somatotroph cells, it inhibits adenylyl cyclase. Intracellular cAMP drops. Growth hormone secretion slows. Downstream, IGF-1 production in the liver follows GH levels downward. SST2 activation also engages tyrosine phosphatase pathways that carry separate antiproliferative effects on tumor cells.

A secondary target, SST5, gets moderate-affinity binding. SST5 activation reduces intracellular calcium, adding another layer of hormone suppression and cell proliferation control. Activity at SST1, SST3, and SST4 is minimal.

The depot formulation is what makes monthly dosing work. Lanreotide sits in a supersaturated solution that, once injected deep subcutaneously, forms a gel deposit at the site. Drug releases slowly from that gel over 28 days. Peak serum concentration hits within the first 24 hours; levels stay above 1 ng/mL through the entire dosing interval. True pharmacokinetic steady state builds over 4 to 5 injections.

In neuroendocrine tumors, the combined SST2 and SST5 actions suppress tumor-derived hormone release (reducing carcinoid syndrome symptoms like flushing and diarrhea) while simultaneously slowing tumor cell division.

Lanreotide (Somatuline Depot) Benefits

  • Lanreotide benefits center on hormonal normalization and tumor growth control in two FDA-approved conditions.
  • GH and IGF-1 levels normalize in 39 to 70% of acromegaly patients, depending on baseline severity and dose (FDA Prescribing Information, 2024).
  • The CLARINET trial (204 patients)[1] showed 53% risk reduction in GEP-NET progression, with 65% of patients progression-free at 24 months.
  • PRIMARYS (90 patients)[2] found 63% of treatment-naive acromegaly patients achieved at least 20% pituitary tumor volume reduction by 48 weeks.
  • One pre-filled syringe every 28 days; no reconstitution, no measurement, no mixing. Patients and community forums consistently cite this as a major adherence advantage over daily or weekly alternatives.
  • Carcinoid syndrome symptoms (flushing episodes, diarrhea from serotonin excess) drop meaningfully on the 120 mg dose, per ELECT trial data and consistent patient reports in r/neuroendocrine.
  • STARTER-NET (ASCO GI 2025) established a new combination: lanreotide plus everolimus pushed median PFS to 29.7 months versus 13.6 for everolimus alone in G1/G2 GEP-NETs with poor prognostic features (HR 0.44, p=0.00016).

Lanreotide (Somatuline Depot): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 6 key studies·FDA-approved

FDA-approved for acromegaly and GEP-NETs with strong Phase III evidence.

Dosing studied: Acromegaly: 90mg q28d (start), titrate to 60-120mg based on GH/IGF-1. Hepatic impairment (mod-severe): cap 60mg q28d. GEP-NETs/carcinoid syndrome: 120mg q28d fixed.
Read the evidence (key study, limitations)

Normalizes GH/IGF-1 in 39-70% of acromegaly patients; reduces GEP-NET progression risk by 53% (CLARINET). 2025 Phase III (STARTER-NET) established everolimus + lanreotide as emerging first-line doublet for G1/G2 GEP-NETs with adverse features.

Key Study

CLARINET (NEJM 2014, PMID 25014687): mPFS 32.8 vs 18.0 months, 53% risk reduction; PRIMARYS (JCEM 2014, PMID 24423301): 63% of acromegaly patients achieved ≥20% pituitary tumor shrinkage at 48 weeks; STARTER-NET (ASCO GI 2025): everolimus+lanreotide mPFS 29.7 vs 13.6 months (HR 0.44, p=0.00016)

Limitations

Long-term gallstone risk 20-33% (requires annual ultrasound monitoring). Glycemic destabilization in diabetics. No head-to-head RCT vs octreotide LAR for superiority in acromegaly (SWITCH trial ongoing). Antibody formation in ~7% reduces long-term efficacy. High cost (~$2,400-4,600/injection) limits access without insurance.

Community Experience
Weak
3.8/5
Based on limited structured community data. Synthesized from r/neuroendocrine, r/acromegaly, online patient reviews, and MSK/Cleveland Clinic patient education materials. Not quantified.

Exclusively used in clinical settings for acromegaly and GEP-NETs.

Community dosing: 90-120mg q28d per clinical indication. No off-label community dosing protocols identified.
Read the reports (what users report 4, common issues 5)

No biohacking or wellness community adoption. Patient-reported outcomes in disease forums broadly align with clinical trial data. GI side effects and injection site reactions are the dominant tolerability complaints. Monthly injection schedule is strongly preferred over daily/weekly alternatives.

What users report (4)
  • Monthly injection schedule highly preferred over daily/weekly alternatives: strong adherence driver
  • Significant reduction in carcinoid syndrome symptoms: flushing frequency and diarrhea episodes
  • Acromegaly patients report ring/shoe size stabilization, reduced sweating, improved joint pain over 3-6 months
  • Pre-filled syringe with no reconstitution or measurement is consistently cited as a convenience advantage
Common issues (5)
  • Diarrhea very common early (SSA-induced fat malabsorption; dietary fat restriction helps)
  • Gallstones develop in 20-33% of long-term users: often asymptomatic but subset requires cholecystectomy
  • Injection site pain and palpable nodules reported more frequently in real-world than in trials
  • Blood sugar dysregulation (both hyper- and hypoglycemia) requires frequent monitoring in diabetic patients
  • Extremely high cost creates access barriers without insurance or pharmaceutical assistance programs
Science-Only Evidence

Lanreotide is used exclusively in supervised clinical practice for serious medical conditions (acromegaly, GEP-NETs, carcinoid syndrome). No biohacking, performance-enhancement, or wellness community use identified. Community-reported experience reflects patient experience with FDA-approved indications only: no divergent dosing approaches or community-discovered protocols.

Lanreotide (Somatuline Depot) Dosage Guide

FDA LabelSomatuline Depot (lanreotide) FDA Prescribing Information (2024)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner90 mgEvery 4 weeks
Moderate90 mgEvery 4 weeks
Aggressive120 mgEvery 4 weeks
Note:

Lanreotide is different from most peptides on this platform. There is no vial to reconstitute, no bacteriostatic water, no insulin syringe math. It arrives as a pre-filled syringe in three strengths: 60 mg (0.3 mL), 90 mg (0.3 mL), and 120 mg (0.5 mL). You inject the full contents. That's it.

The catch is that this is a deep subcutaneous injection into the upper outer quadrant of the buttock, not a typical belly or thigh pinch. Many patients have a healthcare provider do it, at least initially.

Cold chain matters. Store at 2 to 8 degrees Celsius. Pull the syringe out 30 minutes before injection to reach room temperature; cold gel is thicker and harder to push through the needle.

One thing beginners miss: GI side effects in the first month are not a sign that something went wrong. They are expected. Low-fat meals (under 40 g/day) and pancreatic enzyme supplements help considerably.

Alternate left and right buttock each month. Superficial injection worsens nodule formation.

Cycling

No scheduled off period.

Lanreotide is used continuously as long as clinical benefit is maintained. For acromegaly, it is typically a lifelong treatment unless surgery or radiation achieves remission. For GEP-NETs, treatment continues until disease progression or unacceptable toxicity. Dose adjustments are made based on GH/IGF-1 levels (acromegaly) or tumor response (GEP-NETs).

Calculate your Lanreotide (Somatuline Depot) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Lanreotide (Somatuline Depot) Protocols by Goal

beginnerFDA LabelContinuous (indefinite) unless surgery or radiation achieves remission
Initiation
Wk 1-12
90mg · Every 28 days (q28d) · Deep subcutaneous (upper outer quadrant of buttock)
Titration
Wk 13+
60-120mg (individualized by GH/IGF-1 response) · Every 28 days (q28d) · Deep subcutaneous (upper outer quadrant of buttock)

Expected: 39-70% GH/IGF-1 normalization at 3-6 months; 63% pituitary tumor volume reduction ≥20% by 48 weeks (PRIMARYS trial)

Monitor: GH random (target <1 ng/mL), IGF-1 age/sex-adjusted, gallbladder ultrasound (baseline then annually), fasting glucose, TSH, blood pressure, resting heart rate

How to Inject Lanreotide (Somatuline Depot)

  1. 1
    Step 1

    Remove the pre-filled syringe from the refrigerator and let it sit at room temperature for 30 minutes. Do not microwave or use hot water to warm it.

  2. 2
    Wash hands thoroughly

    Choose the upper outer quadrant of one buttock (alternate sides each month).

  3. 3
    Step 3

    Clean the injection site with an alcohol swab and let it dry.

  4. 4
    Remove the needle cap

    Do not prime or expel any air; the syringe is ready to use as-is.

  5. 5
    Pinch the skin firmly

    Insert the needle at a 90-degree angle, rapidly, to its full depth. This is a deep subcutaneous injection.

  6. 6
    Inject slowly and steadily

    The gel is viscous, especially the 120 mg (0.5 mL) syringe. Expect it to take 10 to 20 seconds.

  7. 7
    Withdraw the needle quickly

    Do not rub the injection site afterward; gentle pressure with gauze is fine.

  8. 8
    Step 8

    Dispose of the syringe in a sharps container immediately.

  9. 9
    Step 9

    The three syringe strengths: 60 mg in 0.3 mL, 90 mg in 0.3 mL, 120 mg in 0.5 mL. There is no dose adjustment by volume; you always inject the full syringe.

  10. 10
    Repeat every 28 days

    Mark your calendar. Consistency in the 28-day cycle keeps serum levels in the therapeutic range.

Lanreotide (Somatuline Depot) Stacking Protocols

Works With

Everolimus (Afinitor)

STARTER-NET Phase III (ASCO GI 2025): lanreotide 120mg q28d + everolimus 10mg daily improved mPFS from 13.6 to 29.7 months (HR 0.44, p=0.00016) vs everolimus alone in G1/G2 GEP-NETs with poor prognostic features (Ki-67 5-20% or diffuse liver metastases). Combined antiproliferative effect: SSA suppresses GH/IGF-1 → reduces mTOR input; everolimus directly inhibits mTORC1.

Lanreotide 120mg q28d + everolimus 10mg orally daily. Dose reduce/hold everolimus for grade ≥2 mucositis, hyperglycemia, or pneumonitis. Grade 3+ toxicity rate 35.6%: requires active management.

Cabergoline (dopamine agonist)

Off-label combination for acromegaly with partial GH/IGF-1 control on SSA monotherapy. Meta-analyses show 30-40% additional IGF-1 normalization rate with combined SSA + cabergoline vs SSA alone. Cost-effective add-on step before escalating to pegvisomant.

Cabergoline 0.5-2mg twice weekly added to lanreotide in acromegaly patients with IGF-1 1.0-1.5x ULN despite 90-120mg lanreotide q28d.

Pegvisomant (Somavert)

GH receptor antagonist for acromegaly refractory to SSA alone. Combination with lanreotide allows lower pegvisomant doses with maintained IGF-1 normalization while preserving SSA antiproliferative effect on pituitary tumor. Used in ~15% of acromegaly patients at specialized centers.

Lanreotide 90-120mg q28d + pegvisomant 10-20mg daily SC (adjusted monthly by IGF-1). Requires monthly liver function monitoring (hepatotoxicity risk).

Avoid

Lu-177-DOTATATE (Lutathera): concurrent dosing

Somatostatin analogs compete with Lutathera for SSTR binding at tumor sites, reducing PRRT uptake and efficacy. FDA label mandates discontinuing lanreotide 4-6 weeks before each Lutathera dose. Can resume lanreotide as SSA backbone maintenance between PRRT cycles.

Do not combine
Cyclosporine

Lanreotide reduces cyclosporine bioavailability (altered GI motility + possible CYP3A4 modulation). Clinically significant interaction: cyclosporine blood levels may fall below therapeutic range. Monitor trough levels closely and adjust cyclosporine dose.

Antidiabetic drugs (insulin, sulfonylureas)

Lanreotide suppresses both insulin and glucagon secretion, unpredictably shifting glycemic balance. Net effect depends on indication and baseline. Diabetics may experience either hypoglycemia or hyperglycemia after dose initiation or change. Frequent monitoring and dose adjustment required.

Bradycardic drugs (beta-blockers, non-dihydropyridine CCBs, digoxin)

Lanreotide slows resting heart rate via sinus node modulation. Additive bradycardia with concurrent HR-reducing agents. Obtain baseline ECG; monitor resting HR. Clinically significant if resting HR falls <50 bpm or conduction abnormality develops.

Estimated Cost

Brand Price
Somatuline Depot (Ipsen): ~$3,280 (60mg), ~$3,900 (90mg), ~$4,200-4,600 (120mg) per pre-filled syringe (retail/WAC estimate; ASP declining >25% since 2022 following generic entry). Ipsen copay assistance: up to $20,000/year savings for commercially insured patients (approximately 13 injections or savings cap).
Generic / Research
Generic lanreotide (Cipla, AB-rated, FDA final approval May 22, 2024; launched May 23, 2024): ~$2,435 per 120mg injection (typical US cash price with discount card, April 2026). Medicare J-code J1932: ~$32.19/unit payment rate (Q2 2026).

Pricing updated 2026-04-09

Lanreotide (Somatuline Depot) Side Effects

Gallstones. That is the side effect that separates lanreotide from most other peptide therapies. Somatostatin analogs reduce gallbladder contractility, and over time, bile stasis leads to stone formation in 20 to 33% of long-term users. A 2026 analysis pooled polycystic kidney and liver disease trials with FDA adverse event reports [3]. Cholelithiasis was the most common biliary event for lanreotide, octreotide and pasireotide. Its authors concluded that "younger patients or those receiving pasireotide are at higher risk of cholelithiasis." Most stones are asymptomatic. A subset will need cholecystectomy. Annual gallbladder ultrasound is not optional; it is part of every prescribing guideline for this drug.

Diarrhea affects 35 to 65% of patients and is the most common early complaint. It hits hardest in the first one to three injections. The mechanism is fat malabsorption: somatostatin analogs suppress pancreatic lipase secretion, so dietary fat passes through undigested. Restricting fat intake to under 40 grams per day and adding oral pancreatic enzyme supplementation helps most patients. By month three, the majority have adapted.

Abdominal pain (34%) and nausea/vomiting (19%) follow the same early-onset, dose-dependent pattern. These GI effects are the leading reason patients ask about discontinuation.

Hyperglycemia (14%) is a concern that requires context. Lanreotide suppresses both insulin and glucagon secretion. The net glycemic effect is unpredictable. Some patients run higher; some diabetic patients actually experience hypoglycemia as glucagon drops. Anyone with diabetes needs daily glucose monitoring for at least four weeks after starting or changing dose. Antidiabetic medication adjustments should involve an endocrinologist.

Injection site reactions (15%) include pain, induration, and palpable nodules at the buttock injection site. Proper technique matters: full-depth insertion at a 90-degree angle and strict left-right alternation each month reduces nodule formation. Superficial injection makes it worse.

Headache (16%), musculoskeletal pain (19%), and hypertension (14%) are all reported at rates worth knowing about.

Bradycardia is less common but clinically important. Lanreotide modulates sinus node activity. Resting heart rate can drop below 50 bpm in patients already taking beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. A baseline ECG is standard practice. If resting heart rate falls below 50 or conduction abnormalities appear, the combination needs re-evaluation.

Hypothyroidism can develop because somatostatin analogs suppress pituitary TSH secretion. Thyroid function testing every six months catches this early.

Depression is reported in about 7% of patients, a number that often gets overlooked in the GI-focused side effect conversation.

Antibody formation occurs in roughly 7% of long-term users and can gradually erode biochemical control. Rising IGF-1 levels on a stable dose may be the first sign.

Pregnancy is a contraindication. Lanreotide is FDA Category C. Animal data suggests potential fetal harm. Breastfeeding is not recommended because it is unknown whether lanreotide passes into human milk.

If diarrhea persists past three months, if gallbladder pain develops, if blood sugar swings become unmanageable, or if resting heart rate drops below 50, contact the prescribing physician. These are signals that need clinical attention, not something to wait out.

Common Issues & Solutions

Diarrhea and fat malabsorption: SSAs reduce pancreatic lipase secretion. Low-fat diet (<40g fat/day) and oral pancreatic enzyme supplementation can significantly reduce GI side effects. Most patients adapt within 2-3 months; diarrhea that persists beyond month 3 warrants dietary assessment.

Gallstones (asymptomatic): Do not discontinue lanreotide for asymptomatic cholelithiasis: the clinical benefit of SSA therapy typically outweighs gallstone risk. Symptomatic cholelithiasis may require cholecystectomy, after which lanreotide can usually be continued.

Insufficient IGF-1 control at 90mg (acromegaly): Increase to 120mg q28d before declaring SSA failure. If IGF-1 remains >1.5x ULN at 120mg for 6 months, add cabergoline 0.5-2mg twice weekly as first add-on step (lower cost and risk vs pegvisomant). Reserve pegvisomant combination for confirmed cabergoline non-responders.

Injection site nodule: Common with deep SC gel depot. Ensure strict alternation between left and right upper outer buttock each month. Full-depth 90° angle insertion is critical: superficial injection worsens nodule formation. Nodules typically resolve with proper site rotation.

Glycemic instability in diabetics: Lanreotide suppresses insulin secretion (→ hyperglycemia) and glucagon (→ hypoglycemia); net effect varies. Recommend daily glucose logging for 4 weeks after initiation or dose change. Coordinate insulin or oral hypoglycemic adjustments with endocrinology.

Ask AI about this page

Ask AI for a second opinion on Lanreotide (Somatuline Depot) dosing and side effects

Contraindications

  • Known hypersensitivity to lanreotide or any component of the formulation
  • Pregnancy (FDA Category C: may cause fetal harm based on animal data)
  • Breastfeeding: not recommended; unknown if lanreotide is excreted in human milk
  • Uncontrolled diabetes mellitus (may worsen glycemic control)
  • Severe hepatic impairment (dose adjustment required in moderate impairment)
  • Severe renal impairment (dose adjustment required)

Drug Interactions

  • Lutetium Lu-177 dotatate (Lutathera): discontinue lanreotide before each Lutathera dose; somatostatin analogs compete for receptor binding and may reduce Lutathera efficacy
  • Insulin and oral hypoglycemics: lanreotide may alter glucose regulation; dose adjustments of antidiabetic drugs may be needed
  • Cyclosporine: decreased blood levels of cyclosporine; monitor levels closely
  • Bromocriptine: increased bioavailability of bromocriptine; monitor for dopamine agonist side effects
  • Beta-blockers, calcium channel blockers, and other drugs that slow heart rate: additive bradycardia risk
  • Drugs metabolized by CYP3A4: somatostatin analogs may reduce metabolic clearance of some substrates

Product Quality

Recommended Monitoring

TestWhenTarget
GH (random serum)Baseline, then at months 3, 6, 12, then every 6 months (acromegaly)<1 ng/mL (random) on SSA therapy; <0.4 ng/mL on oral glucose tolerance test for strict biochemical remission
IGF-1 (age- and sex-adjusted)Baseline, then months 3, 6, 12, every 6 months (acromegaly and GEP-NETs)Within age/sex-adjusted normal range (laboratory-specific reference)
Gallbladder ultrasoundBaseline, then annuallyNo gallstones; if found, monitor size and symptom development: most are managed conservatively
Fasting blood glucose and HbA1cBaseline, then every 3-6 months (more frequent in diabetics or at dose change)FBG 70-100 mg/dL (non-diabetic); per individualized diabetes targets in diabetics
Thyroid function (TSH, free T4)Baseline, then every 6 monthsTSH 0.4-4.0 mIU/L; free T4 within normal limits
Liver function tests (ALT, AST, ALP, bilirubin)Baseline, then every 6-12 months (monthly if on concurrent pegvisomant or everolimus)Within normal limits; <3x ULN in oncology combination context (per individual regimen tolerance)
Heart rate and ECGBaseline ECG; monitor HR at each visit; repeat ECG if symptomatic or on concomitant bradycardic drugsResting HR >50 bpm; PR interval <200 ms
Chromogranin A (CgA)Baseline, then every 3-6 months (GEP-NETs)Stable or declining from baseline (laboratory-specific; note proton pump inhibitors elevate CgA: account for this)
Cross-sectional imaging (CT or MRI abdomen/pelvis)Baseline, then every 3-6 months for first year (GEP-NETs); every 6 months if stableStable disease or partial/complete response; progressive disease by RECIST triggers treatment change
GH (random serum)

Primary efficacy marker for acromegaly; guides dose titration decisions

IGF-1 (age- and sex-adjusted)

Integrated GH exposure marker; primary titration endpoint in acromegaly. Also monitoring target in GEP-NETs where IGF-1 axis may be relevant.

Gallbladder ultrasound

Somatostatin analogs reduce gallbladder motility and bile flow, causing 20-33% cumulative cholelithiasis incidence

Fasting blood glucose and HbA1c

Lanreotide alters glucose homeostasis by suppressing both insulin and glucagon secretion; net glycemic effect is unpredictable

Thyroid function (TSH, free T4)

SSAs can suppress TSH secretion from pituitary and cause subclinical or overt hypothyroidism

Liver function tests (ALT, AST, ALP, bilirubin)

Monitor for drug-related hepatotoxicity, especially with combination regimens; also relevant if biliary obstruction from gallstones develops

Heart rate and ECG

Lanreotide causes sinus bradycardia; additive risk with beta-blockers, non-dihydropyridine calcium channel blockers, and digoxin

Chromogranin A (CgA)

Tumor burden marker for neuroendocrine tumors; rising CgA may precede radiographic progression and can trigger imaging

Cross-sectional imaging (CT or MRI abdomen/pelvis)

Assess tumor response and progression per RECIST 1.1 to guide continuation vs switch of therapy

Lanreotide (Somatuline Depot) Before and After

Month 1
First injection

GH levels begin to decline within hours. GI side effects (diarrhea, abdominal pain) are most common during the first few injections. Serum lanreotide concentrations reach therapeutic levels within the first day.

Months 2-3

Steady-state drug levels approach with repeated dosing. GH and IGF-1 levels show measurable reduction. GI side effects often improve as the body adapts. Dose titration may be initiated based on GH/IGF-1 response.

Months 3-6

Steady-state pharmacokinetics fully established by the 4th-5th injection. Significant IGF-1 normalization expected in responders. Tumor volume reduction detectable on imaging in acromegaly patients. GEP-NET tumor stabilization assessable.

Months 6-12

Optimal hormonal control achieved with dose adjustments. PRIMARYS trial showed 63% of patients had ≥20% tumor shrinkage by 48 weeks. Long-term gallbladder monitoring should begin. Symptom improvement in acromegaly (headache, sweating, joint pain).

Year 1+

Continued long-term treatment with periodic monitoring of GH, IGF-1, liver function, glucose, thyroid function, and gallbladder ultrasound. CLARINET trial showed 65% progression-free survival at 24 months for GEP-NETs. Dose extended to every 6-8 weeks in some well-controlled acromegaly patients.

What to Expect

Month 1 (first injection): GH levels start dropping within hours of the first shot. Serum lanreotide hits peak concentration in the first 24 hours and stays above therapeutic levels for the full 28-day interval. Expect diarrhea, abdominal cramps, and flatulence; these are the most common complaints in month one. A palpable nodule at the buttock injection site is normal and not harmful. Nausea affects about 19% of patients during this period.

Months 2 to 3: Drug levels approach steady state. GH and IGF-1 show measurable decline. The first biochemical assessment at month 3 (GH plus IGF-1) determines whether your dose needs titration. GI side effects start easing, especially if you have cut dietary fat. Acromegaly patients often notice reduced headaches and less sweating. Plan meals and schedule around injection day; most patients settle into a routine.

Months 3 to 6: Full steady-state pharmacokinetics lock in after the 4th or 5th injection. Responders show clear IGF-1 normalization. MRI can detect pituitary tumor volume reduction in acromegaly patients. GEP-NET patients get their first imaging assessment for tumor stabilization. Asymptomatic gallstones may show up on ultrasound. Some patients notice resting heart rate dropping a few beats per minute.

Months 6 to 12: PRIMARYS trial data showed 63% of patients with at least 20% pituitary tumor shrinkage by week 48. CLARINET showed 65% progression-free survival at 24 months for GEP-NETs. Dose extension to every 6 to 8 weeks becomes an option for well-controlled acromegaly patients. Long-term gallbladder monitoring kicks in with annual ultrasounds. Patients overwhelmingly prefer the monthly schedule compared to daily injection regimens.

Year 1 and beyond: Most patients maintain long-term efficacy on a stable dose. About 7% develop anti-lanreotide antibodies, which cause a gradual creep in IGF-1 levels detectable on serial bloodwork. Some patients sustain disease control for over a decade. The monthly schedule stays well-accepted. A subset will need cholecystectomy for gallstones but can continue lanreotide after surgery. Insurance prior authorization is a recurring frustration that patients mention frequently.

Detailed Timeline: Science vs Community

Month 1 (first injection)
Science

Serum lanreotide reaches Cmax within 24 hours; GH levels begin declining within hours. Therapeutic concentrations (>1 ng/mL) maintained throughout 28-day interval from first dose.

Community

Diarrhea, abdominal cramps, and flatulence are the most frequently reported first-month complaints. Palpable injection site nodule at buttock injection site common; not harmful.

Months 2-3
Science

Approaching steady-state drug levels. GH and IGF-1 show measurable reduction. First biochemical assessment (GH, IGF-1) at month 3 guides dose titration decision.

Community

GI side effects begin improving; dietary fat restriction helps most patients. First signs of acromegaly symptom improvement: reduced headache and sweating. Patients often need to modify diet and plan around injection day.

Months 3-6
Science

Full steady-state reached after 4th-5th injection. Significant IGF-1 normalization in responders. Pituitary tumor volume reduction detectable on MRI in acromegaly. GEP-NET tumor stabilization assessable by imaging.

Community

Acromegaly patients report ring/shoe size stabilization, reduced joint pain and facial swelling. GEP-NET/carcinoid patients report meaningful reduction in flushing and diarrhea episodes from carcinoid syndrome.

Months 6-12
Science

PRIMARYS: 63% of acromegaly patients achieved ≥20% pituitary tumor shrinkage by 48 weeks. CLARINET: 65% PFS at 24 months for GEP-NETs. Dose extension to q6-8 weeks feasible in some well-controlled acromegaly patients.

Community

Long-term tolerability generally good. Annual gallbladder ultrasound findings (gallstones) are a common surprise for patients who feel well. Monthly injection schedule strongly praised vs daily injection regimens.

Year 1+
Science

Continued efficacy maintained in most patients. ~7% develop anti-lanreotide antibodies leading to gradual loss of biochemical control: detectable through rising IGF-1 on stable dose. Some patients achieve sustained disease control for 10+ years.

Community

Monthly dosing schedule remains well-accepted. Patients report significant quality-of-life improvement vs pre-treatment. A subset require cholecystectomy but continue lanreotide post-operatively. Insurance prior authorization battles are a recurrent stressor.

Pharmacokinetics

Half-Life
624h
Bioavailability
SC (deep): 69-78% (dose-dependent; 73.4% at 60mg, 69.0% at 90mg, 78.4% at 120mg)
Tmax
~24 hours (Cmax within first day); sustained therapeutic levels >1 ng/mL throughout 28-day dosing interval
Data Confidence
high

Source: FDA Prescribing Information (Somatuline Depot), Section 12.3: terminal half-life 23 to 30 days for depot formulation

Pharmacokinetics: Active Dose Over Time

t½ = ~23-30 days (depot formulation)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
8
Structure
Cyclic
Sequence
XCYWKVCT
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 108736-35-2 (free base); 127984-74-1 (acetate salt)PubChem 6918011 (opens in a new tab)

Who Should Consider Lanreotide (Somatuline Depot)

  • Adults with acromegaly who have inadequate response to surgery or are not surgical candidates
  • Adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs
  • Patients with carcinoid syndrome needing symptom control
  • Acromegaly patients as primary medical therapy when surgery is contraindicated

Related Peptides

What Changed for Lanreotide (Somatuline Depot)

  1. Dosing

    Corrected Oct 9, 2026: the lanreotide beginner tier is the 90 mg acromegaly start every 4 weeks, not 60 mg, per the Somatuline Depot label.

    Before: Beginner 60 mg every 4 weeks After: Beginner 90 mg every 4 weeks; 60 mg is the start only with moderate or severe kidney or liver impairment

    Source: Somatuline Depot (lanreotide) prescribing information (openFDA label record, SPL version 16, effective Oct 11, 2024) (opens in a new tab) · Saved copy

  2. Safety

    Younger age and pasireotide were tied to higher gallstone risk across three somatostatin analogs, per Clin Transl Gastroenterol, Jul 20, 2026.

    Before: Gallstones described per drug as a somatostatin analog effect, with no comparison across octreotide, lanreotide and pasireotide. After: Adds a 2026 analysis: gallstones were the most common biliary event for all three; its authors found higher risk in younger patients and with pasireotide.

    What this does not mean: Adverse event reports cannot give rates, and the trials were in polycystic kidney and liver disease. It does not mean octreotide or lanreotide carry a low gallstone risk.

    Also covers: Octreotide (Sandostatin), Pasireotide (Signifor)

    Source: Clinical and Translational Gastroenterology 2026, octreotide, lanreotide and pasireotide in polycystic kidney and liver disease (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]CLARINET: Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors (NEJM 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Tumor Shrinkage With Lanreotide Autogel 120mg as Primary Therapy in Acromegaly: PRIMARYS Trial (JCEM 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Comparative efficacy and safety of octreotide, lanreotide, and pasireotide in ADPKD and polycystic liver disease: network meta-analysis with FAERS data (Mei et al., Clin Transl Gastroenterol 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
N/A: supplied as pre-filled syringe with supersaturated solution
After Reconstitution
N/A: no reconstitution needed
Temperature
2-8°C (36-46°F); protect from light. May be kept at room temperature for up to 30 minutes before injection.

Frequently Asked Questions

Lanreotide (Somatuline Depot) is FDA-approved for acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CLARINET trial showed a 53% reduction in tumor progression risk in 204 GEP-NET patients (PMID 25014687). It is also used off-label for carcinoid syndrome symptom control.

Deep subcutaneous injection: 60 mg, 90 mg, or 120 mg every 4 weeks. For GEP-NETs: 120 mg every 4 weeks (CLARINET dose). For acromegaly: start at 60-90 mg every 4 weeks and titrate based on GH and IGF-1 levels. The prefilled syringe is injected into the upper outer quadrant of the buttock.

Both are somatostatin analogs binding SSTR2 and SSTR5. Lanreotide has a 23-30 day half-life (depot formulation) vs octreotide LAR at roughly 28 days. Lanreotide is self-injectable via prefilled deep SC syringe; octreotide LAR requires IM injection by a healthcare provider. Efficacy in GEP-NETs is comparable between the two in indirect comparisons.

Diarrhea (26-37%), abdominal pain (19%), and injection site reactions (9-22%) are the most common. Gallstone formation occurs in 14-23% on long-term therapy. Bradycardia and glucose dysregulation require monitoring. The deep SC injection can cause nodules at the injection site that typically resolve within weeks.

The half-life of Lanreotide (Somatuline Depot) is ~23-30 days (depot formulation). This determines how frequently you need to dose for consistent blood levels.